- Home
- Companies
- north america
- drugs design
Refine by
Drugs Design Suppliers In North America
54 companies found
based inSacramento, CALIFORNIA (USA)
Ainnocence is a next-generation biotech aiming to create a self-evolving modularized intelligent platform that integrates various advanced computational and wet lab technologies to revolutionize the drug discovery and development process. We ...
Simple : CarbonAI searches over 1.9 billion compounds to create synthesizable drug candidates – based only on target sequence. Precise : CarbonAI accurately identifies the most active and safe compound with a multi-objective optimization ...
based inMalmö, SWEDEN
Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. Oncoral is a novel oral irinotecan tablet in ...
Mangoral is a novel oral imaging agent in development for use in MR-imaging of the liver. Mangoral aims to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with severe kidney ...
based inDaejeon, SOUTH KOREA
We are exploring sequence-based drug discovery and development, which is bypassing the need for 3D structure. ...
Dr. UG is an AI platform for developing new drugs that is based on DEARGEN’s deep learning technology. It specializes in genome data analysis, biomarker prediction, molecule selection and optimization. DEARGEN discovers new ...
based inSan Francisco, CALIFORNIA (USA)
Atomwise is a technology-enabled pharmaceutical company leveraging the power of AI to revolutionize small molecule drug discovery. The Atomwise team invented the use of deep learning for structure-based drug design; this technology underpins ...
based inParis, FRANCE
Ariana Pharma is a leading Al driven Precision Medicine Company focused on accelerating clinical drug development and designing advanced therapeutic decision support systems. Using its KEM Explainable Artificial Intelligence (XAl) technology, Ariana ...
based inWatertown, MASSACHUSETTS (USA)
Since its inception, Windgap Medical has been revolutionizing drug delivery devices and the medicine they contain to create simple, safe, and stable solutions for today’s most concerning health conditions. With 85+ issued patents, Windgap seeks to ...
based inAlpharetta, GEORGIA (US) (USA)
Clearside Biomedical is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®). The platform provides an in-office, repeatable, non-surgical procedure, offering targeted ...
based inSan Carlos, CALIFORNIA (USA)
Alkahest is a clinical stage biopharmaceutical company targeting neurodegenerative and age-related diseases with transformative therapies derived from a deep understanding of the plasma proteome in aging and ...
One the key chronokine targets identified using Alkahest’s platform is eotaxin. Eotaxin is an immunomodulatory chemokine that is increased in normal aging as well as multiple diseases of aging. It has been implicated in Alzheimer’s ...
based inCarlsbad, CALIFORNIA (USA)
Our mission is to pioneer a new branch of medicine based on transplanting specific cell types to patients with serious medical conditions. Lineage’s programs are based on the Company’s proprietary cell-based therapy platform and associated ...
OPC1 is an oligodendrocyte progenitor cell therapy that is currently in a Phase 1/2a multicenter clinical trial for acute spinal cord injuries (SCI). Oligodendrocyte progenitor cells (OPCs) are naturally-occurring precursors to the cells which ...
based inVancouver, BRITISH COLUMBIA (CANADA)
Zymeworks Inc. is a publicly listed (NYSE: ZYME), clinical-stage, biopharmaceutical company dedicated to the discovery, development, and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of ...
Zymeworks’ lead product candidate, zanidatamab, is a HER2-targeted bispecific antibody developed using Zymeworks proprietary Azymetric platform. Zanidatamab is currently being evaluated in global Phase 1, Phase 2 and pivotal clinical trials as ...
based inBryan, TEXAS (USA)
At iBio, we are using our RubrYc® Discovery Platform to tackle complex and challenging drug targets, with the goal of developing safer and more effective immunotherapies for difficult-to-treat cancers. We envision a world where drug discovery is ...
Idiopathic pulmonary fibrosis [IPF] is a form of progressive pulmonary fibrosis, or abnormal scarring of the lungs. As the disease progresses, the increased scarring leads to decreasing transfer of oxygen into the bloodstream, and ultimately, ...
based inBerkeley, CALIFORNIA (USA)
InterX, led by Nobel Prize-winning scientists, is developing tools for pharmaceutical ligand design, material science, and biochemistry. We leverage our proprietary software tools for internal molecule development work, as well as joint ventures. ...
InterX Development Division focuses on bridging the risk gap in Drug Discovery from drug targets to novel candidates. The Development Division applies InterX’s proprietary computer-aided drug ...
based inMalvern, PENNSYLVANIA (USA)
We are a clinical stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. We leverage our expertise in superoxide dismutase ...
based inGermantown, MARYLAND (USA)
VeraChem LLC was founded in 2000 to advance the state of the art in computer-aided drug-discovery and molecular design by developing computational chemistry methods that are based on cutting edge basic science, but are also applicable in applied ...
based inSan Francisco, CALIFORNIA (USA)
The invenious platform aims to enhance safety, efficacy, sterility, value and convenience. BioQ designs ready-to-use delivery systems for hard to prepare and hard to administer infusible drugs – thereby simplifying the infusion process from ...
based inBoston, MASSACHUSETTS (USA)
CervoMed is a clinical stage company dedicated to the development and commercialization of drug treatments for neurodegenerative diseases with a focus on the early stages of the neurodegenerative process. Until August 2023, CervoMed was known as ...
Our lead product candidate, Trans sodium crocetinate (TSC), is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, a serious complication of many of medicine’s most intractable and ...
based inBozeman, MONTANA (USA)
Microbion is a clinical-stage pharmaceutical company developing a novel class of compounds for the treatment of difficult-to-treat infections, including chronic infections and antibiotic-resistant infections. Microbion is dedicated to developing ...
Cystic Fibrosis (CF) lung disease, which is estimated to affect more than 30,000 in the US and 70,000 worldwide1, is characterized by chronic bacterial infection and severe inflammation that leads to progressive deterioration in lung function. ...
based inIthaca, NEW YORK (USA)
MiTeGen designs, manufactures and distributes products for cryo-em (cryo electron microscopy), crystallization, crystallography and X-ray diffraction of proteins, viruses and small molecule/inorganic compounds, and for manipulation and measurement ...
based inNanjing, CHINA
PharmaBlock Sciences (Nanjing), Inc. (SZSE:300725) is a leading provider of innovative chemistry products and services throughout the pharmaceutical R&D process and commercial production. Its core businesses include a rationally designed building ...
Virtual screening is a computational approach used to search libraries of small molecules in order to identify hit and even lead compounds. Because of its significantly lower cost, shorter turnaround time, and particularly access to libraries with ...
based inSouth San Francisco, CALIFORNIA (USA)
Sutro Biopharma is a clinical stage company pioneering a compelling and unique way of discovering, developing and manufacturing therapeutics. Our focus is aimed primarily on next-generation cancer therapeutics – antibody drug conjugates, bispecific ...
